CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.

Trends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

ONCOGENE is a premier peer-reviewed journal published by SpringerNature, serving as a crucial platform for innovative research within the fields of Cancer Research, Genetics, and Molecular Biology. With an impressive Impact Factor and a distinguished Q1 ranking across major categories, ONCOGENE publishes cutting-edge studies aimed at unraveling the complexities of cancer biology and genetic mechanisms. The journal has been a vital resource for the academic community since its inception in 1987, and it continues to foster rigorous scientific discussions and collaborations. Researchers, professionals, and students can access a wealth of critical insights and advances in cancer genomics and therapeutic approaches, cementing ONCOGENE’s role as a leading voice in the landscape of biomedical research. For comprehensive academic research, ONCOGENE remains an indispensable source of knowledge with contributions that significantly impact the evolution of cancer research and treatment strategies.

NATURE REVIEWS CANCER, a premier journal published by NATURE PORTFOLIO, stands as a cornerstone in the field of oncology, focusing on delivering high-quality, comprehensive reviews that shape our understanding of cancer biology, prevention, and treatment. With an impressive impact in the academic community, it ranks Q1 in both Cancer Research and Oncology categories as of 2023, further denoted by a remarkable Scopus ranking as the top journal in Cancer Research and second in Oncology. This ensures that published articles not only set the standard for scientific excellence but also drive significant advancements in cancer research methodologies and practices. The journal's targeted audience, including researchers, practitioners, and students, will greatly benefit from its insightful analyses and interdisciplinary approach. While it operates under a traditional subscription model, the rich content and vast expertise presented in its articles foster a global dialogue on cancer-related issues, making it an essential resource for anyone dedicated to the advancement of cancer science.

SEMINARS IN CANCER BIOLOGY is a leading journal dedicated to the dissemination of groundbreaking research in the field of cancer biology. Published by Academic Press Ltd - Elsevier Science Ltd, this esteemed journal plays a pivotal role in the academic community, boasting a prestigious impact factor and ranking within the Q1 category in Cancer Research for 2023. With an exceptional Scopus rank of #11 out of 230 in the realms of Biochemistry, Genetics, and Molecular Biology, it holds a significance that underscores its influence in advancing the understanding of cancer mechanisms and therapies. Established in 1990, the journal fosters a comprehensive platform for sharing high-quality and innovative research, critical reviews, and expert opinions aimed at professionals and researchers in the field. While not an open-access journal, it provides valuable insights that enhance the collective knowledge essential for the fight against cancer. For researchers, clinicians, and students, SEMINARS IN CANCER BIOLOGY is a crucial resource, paving the way for new discoveries and innovations in cancer treatment and prevention.

Cancer Communications, published by WILEY, is a leading open-access journal that has positioned itself at the forefront of cancer research and oncology since its inception in 2017. With an impressive HIndex reflective of its scholarly impact and recognized in the Q1 category for both Cancer Research and Oncology as of 2023, this journal consistently ranks in the top echelons of its field, specifically at Rank #16/404 and Rank #13/230 in their respective categories on Scopus. Cancer Communications aims to disseminate cutting-edge research findings, innovative methodologies, and significant advancements in cancer treatments, thereby fostering a deeper understanding of oncology among researchers, healthcare professionals, and students. The journal operates under an Open Access model since 2018, ensuring that vital research is accessible to a global audience, thus enhancing collaboration and knowledge sharing necessary to tackle one of the most pressing health challenges of our time. Located in Hoboken, NJ, United States, and with a strong commitment to scientific excellence, Cancer Communications remains an essential resource for anyone engaged in the fight against cancer.

Nature Cancer, published by NATURE PORTFOLIO, stands at the forefront of oncological research with a robust impact within the scientific community. As an esteemed journal with impressive rankings—#12 in Medicine (Oncology) and #8 in Biochemistry, Genetics and Molecular Biology (Cancer Research) according to Scopus, placing it within the 97th and 96th percentiles respectively—Nature Cancer boasts a Q1 category status in both Cancer Research and Oncology for 2023. The journal's commitment to advancing cancer research is crucial, promoting high-quality, peer-reviewed studies that address the complexities of cancer biology and treatment. By facilitating open access to impactful findings, Nature Cancer aims to foster collaboration and inspire innovative approaches among researchers, professionals, and students alike, making significant strides in the global fight against cancer. As this pivotal publication continues its converged years from 2020 to 2024, it heralds a future ripe with transformative insights and breakthroughs in the vital field of oncology.

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.